The CCL20-CCR6 axis represents a well-established therapeutic target in autoimmune disorders including inflammatory bowel disease (IBD), psoriasis (PS), and rheumatoid arthritis (RA) (95). Here, CCR6 is linked to rheumatoid arthritis.